69 related articles for article (PubMed ID: 12655444)
1. Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts.
Feng N; Jin H; Wang M; Du C; Wright JA; Young AH
Cancer Chemother Pharmacol; 2003 Mar; 51(3):247-55. PubMed ID: 12655444
[TBL] [Abstract][Full Text] [Related]
2. Macrophages play a critical role in the anti-tumor activity of Virulizin.
Du C; Feng N; Jin H; Lee V; Wang M; Wright JA; Young AH
Int J Oncol; 2003 Nov; 23(5):1341-6. PubMed ID: 14532975
[TBL] [Abstract][Full Text] [Related]
3. Virulizin, a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo.
Li H; Cao MY; Lee Y; Benatar T; Lee V; Feng N; Gu X; Liu P; Jin H; Wang M; Der S; Lightfoot J; Wright JA; Young AH
Int Immunopharmacol; 2007 Oct; 7(10):1350-9. PubMed ID: 17673150
[TBL] [Abstract][Full Text] [Related]
4. Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts.
Liu C; Ferdinandi ES; Ely G; Joshi SS
Int J Oncol; 2000 May; 16(5):1015-20. PubMed ID: 10762639
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy of Virulizin in human breast, ovarian and prostate tumor models.
Du C; Feng N; Jin H; Wang M; Wright JA; Young AH
Anticancer Drugs; 2003 Apr; 14(4):289-94. PubMed ID: 12679733
[TBL] [Abstract][Full Text] [Related]
6. Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages.
Li H; Cao MY; Lee Y; Lee V; Feng N; Benatar T; Jin H; Wang M; Der S; Wright JA; Young AH
Cancer Immunol Immunother; 2005 Nov; 54(11):1115-26. PubMed ID: 15891881
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic response of human tumor xenografts in athymic mice to doxorubicin.
Giuliani FC; Zirvi KA; Kaplan NO
Cancer Res; 1981 Jan; 41(1):325-35. PubMed ID: 7448772
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Abi-Habib RJ; Singh R; Leppla SH; Greene JJ; Ding Y; Berghuis B; Duesbery NS; Frankel AE
Clin Cancer Res; 2006 Dec; 12(24):7437-43. PubMed ID: 17189417
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice.
Horton HM; Hernandez P; Parker SE; Barnhart KM
Cancer Res; 1999 Aug; 59(16):4064-8. PubMed ID: 10463608
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans retinoic acid on the growth of cultured human pancreas cancer cells and pancreas tumor xenografts in immunodeficient mice.
Avila GE; Zheng X; Cui XX; Ryan AD; Hansson A; Suh J; Rabson AB; Chang RL; Shih WJ; Lin Y; Crowell P; Lu YP; Lou YR; Conney AH
J Pharmacol Exp Ther; 2005 Oct; 315(1):170-87. PubMed ID: 15976015
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
14. Virulizin.
BioDrugs; 2002; 16(5):374-5. PubMed ID: 12408741
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models.
De Cesare M; Pratesi G; Veneroni S; Bergottini R; Zunino F
Clin Cancer Res; 2004 Nov; 10(21):7357-64. PubMed ID: 15534112
[TBL] [Abstract][Full Text] [Related]
16. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
[TBL] [Abstract][Full Text] [Related]
17. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
[TBL] [Abstract][Full Text] [Related]
19. Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis.
Saleem M; Maddodi N; Abu Zaid M; Khan N; bin Hafeez B; Asim M; Suh Y; Yun JM; Setaluri V; Mukhtar H
Clin Cancer Res; 2008 Apr; 14(7):2119-27. PubMed ID: 18381953
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of Virulizin in patients with pancreatic cancer.
Warner E; Weinroth J; Chang S; MacDonald M; Strauss B
Clin Invest Med; 1994 Feb; 17(1):37-41. PubMed ID: 8174313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
